Issue 31, 2015

Acid-labile boronate-bridged dextran–bortezomib conjugate with up-regulated hypoxic tumor suppression

Abstract

An acid-labile dextran–bortezomib conjugate (Dex–BTZ), i.e., a macromolecularized proteasome inhibitor, is synthesized by a boron esterification reaction. The prodrug exhibits intracellular acidity-accelerated BTZ release, and up-regulated inhibition efficacies toward hypoxic tumor in vitro and in vivo through both NF-κB- and ERS-mediated apoptosis signaling pathways.

Graphical abstract: Acid-labile boronate-bridged dextran–bortezomib conjugate with up-regulated hypoxic tumor suppression

Associated articles

Supplementary files

Article information

Article type
Communication
Submitted
13 Feb 2015
Accepted
12 Mar 2015
First published
12 Mar 2015

Chem. Commun., 2015,51, 6812-6815

Acid-labile boronate-bridged dextran–bortezomib conjugate with up-regulated hypoxic tumor suppression

W. Xu, J. Ding, L. Li, C. Xiao, X. Zhuang and X. Chen, Chem. Commun., 2015, 51, 6812 DOI: 10.1039/C5CC01371B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements